📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ
A drug from AstraZeneca failed to meet the primary goals of the study.
Jin10 reported on July 16 that AstraZeneca said on Wednesday that its experimental drug Anselamimab did not meet the primary endpoint of late-stage studies for the treatment of AL amyloidosis. AL amyloidosis is a rare disease that causes an increase in protein deposits in the body, leading to significant organ damage.